🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

FibroFind is expanding its workforce and have a new opening for a technical scientist. If you love science and want to work with a young vibrant company advancing the development of new medicines for the treatment of life threatening diseases then do come and join us.

We are expanding our workforce and are now recruiting a Scientific Project Manager. If you love science, enjoy leadership and want to grow your career with a young and exciting company in the healthcare field then come and join us! reed.co.uk/jobs/scientifi…

We are hiring! If you are a PhD level biologist with a strong track record in research using in vitro and/or in vivo models of disease then come and join us cv-library.co.uk/job/214085948/…

We were proud to be presenting with Gilead Sciences at the EASL International Liver Congress on a new study reporting that a combination of ACC inhibitor and FGF-19 reduces steatosis and fibrosis in our precision cut liver slice model of human NASH. #ILC2021 #nash #fibrosis.

FibroFind are delighted to have collaborated with Fibrosis Lab on the discovery of how lipophagy and NASH are suppressed by mTORC1-Plin3 regulated lipophagy. aasldpubs.onlinelibrary.wiley.com/doi/10.1002/he… #nash #liver #fibrosis #inflammation

We are delighted to have contributed to an exciting pre-clinical study with Hepion Pharmaceuticals showing that their drug CRV431 has anti-tumour activity in a model of liver cancer. globenewswire.com/news-release/2… #drugdiscovery #livercancer

Exciting news. We have been shortlisted in two award categories for the Bionow annual awards - start up of the year and exporter of the year. Well done to the entire team! bionow.co.uk/news/b620152ad…

We are excited and grateful to be shortlisted for this prestigious award.

Happy to share a preprint of our work on neutrophils and their role in NASH-HCC immunotherapy. Derek A Mann Owen Sansom 🏳️‍🌈 Leo M. Carlin Cancer Research UK

We are honoured and excited to be shortlisted for Bionow #startup of the Year!

It is a privilege and an honour to be able to support youth development in the city of Newcastle and in particular with Northern Football Club who are making great strides in promoting sporting and physical fitness in girls #InternationalWomensDay

We have only gone and done it, FibroFind are the Bionow Start Up of the Year!!

We are very proud!

Metabolic disturbances caused by hepatitis c virus can persist after successful treatment and can be a risk for development of liver cancer. A review co-authored by Prof Derek A Mann published in Journal of Hepatology. eur03.safelinks.protection.outlook.com/?url=https%3A%…

What a phenomenal achievement and great for our 4 directors all of whom are investigators at Newcastle University

A cool new animation describing how FibroFind are revolutionising the search for new treatments in chronic kidney disease and paving the way for an era in which novel therapeutics are discovered using human rather than animal experimental systems. Enjoy! youtu.be/btJeMH-5uGQ

Latest research output led by our CEO @JelenaMann describing the identification of microRNA regulated pathways within the fibrotic microenvironment of human idiopathic pulmonary fibrosis ajp.amjpathol.org/article/S0002-…

We did it! We bought a site for a new laboratory and office building right in the heart of the great city of Newcastle! Here is an artist impression of what all be FibroFind new home from where we will put the North East of England firmly on the global biomedical sector map.

FibroFind are pleased to be sponsoring the very first First International Conference of Liver Pathobiology: From Bench to Bedside held in Chania, Crete which starts today!

A fascinating new paper describing the role of mitochondrial DNA in regulating the phenotypic features of cellular senescence which is co-authored by our CSO Derek A Mann